An Observational Quality of Life Study in Participants With Rheumatoid Arthritis Treated With Rituximab
sunnuntai 3. tammikuuta 2016 päivittänyt: Hoffmann-La Roche
An Observational, Prospective, Multicenter, Local, to Assess the Quality of Life Through the Use of Questionnaires in a Cohort of Patients With Rheumatoid Arthritis Treated With Anti-CD20 Therapy
This multicenter prospective observational study will evaluate the quality of life in participants with rheumatoid arthritis (RA) who are initiated with rituximab (MabThera/Rituxan).
Participants will be followed for 6 months from initiation of treatment.
Tutkimuksen yleiskatsaus
Tila
Valmis
Ehdot
Opintotyyppi
Havainnollistava
Ilmoittautuminen (Todellinen)
94
Yhteystiedot ja paikat
Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.
Opiskelupaikat
-
-
BA
-
Salvador, BA, Brasilia, 40050-410
-
Salvador, BA, Brasilia, 41810-570
-
-
MG
-
Juiz de Fora, MG, Brasilia, 36036-330
-
Uberlandia, MG, Brasilia, 38405-320
-
-
MS
-
Cuiaba, MS, Brasilia, 78020-450
-
-
PE
-
Recife, PE, Brasilia, 50000-000
-
Recife, PE, Brasilia, 50100-130
-
-
PR
-
Curtiba, PR, Brasilia, 80030-110
-
-
RJ
-
Rio De Janeiro, RJ, Brasilia, 22640102
-
-
RS
-
Porto Alegre, RS, Brasilia, 90610-000
-
-
SP
-
Campinas, SP, Brasilia, 13015-001
-
Campinas, SP, Brasilia, 13073-350
-
Osasco, SP, Brasilia, 06010-080
-
Santo Andre, SP, Brasilia, 09060-650
-
Sao Jose do Rio Preto, SP, Brasilia, 15090-000
-
Sao Paulo, SP, Brasilia, 05403-010
-
Sao Paulo, SP, Brasilia, 04026-000
-
Sao Paulo, SP, Brasilia, 03533-000
-
Sao Paulo, SP, Brasilia, 04041-000
-
Sao Paulo, SP, Brasilia, 1228200
-
-
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)
Hyväksyy terveitä vapaaehtoisia
Ei
Sukupuolet, jotka voivat opiskella
Kaikki
Näytteenottomenetelmä
Todennäköisyysnäyte
Tutkimusväestö
Participants with RA initiating rituximab
Kuvaus
Inclusion Criteria:
- Adult participants of both genders who are 18 years or older
- Diagnosis of RA for at least 6 months according to the criteria of the American College of Rheumatology (ACR) of 1987 for the RA classification
- Participants with medically prescribed or being administered with unique rituximab infusion in the least 3 days, according to the approved label
- Ability to meet the program's requirements and to voluntarily sign the Informed Consent Term.
Exclusion Criteria:
- Participants who have received any investigational medication within less than or equal to (<=) 1 year before the first dose of the currently indicated treatment
- Participants with an active infection
- Participants with conditions that may interfere in the ability to understand the requests of data collection and to obey to the study's requirements
- Functional Class IV defined based on the ACR functionality criteria for RA
- Participants who can not or who do not want, for any reason, to answer the questionnaires.
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Havaintomallit: Kohortti
- Aikanäkymät: Tulevaisuuden
Kohortit ja interventiot
Ryhmä/Kohortti |
|---|
|
Rituximab
Participants who are receiving 1000 milligrams (mg) intravenous (IV) infusion of rituximab on Day 1 and Day 15 as part of standard of care of the treating site will be included in this observational study.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Percentage of Participants Achieving an Improvement of at Least 0.22 Units in Health Assessment Questionnaire (HAQ) at Week 24
Aikaikkuna: Week 24
|
The Health Assessment Questionnaire-Disability Index (HAQ-DI) is a 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping and activities of daily living).
Responses in each functional area are scored from 0 to 3 (0=no difficulty and 3=inability to perform a task in that area).
HAQ-DI total scores expressed as overall mean score with range 0-3: 0-0.25=normal functioning; 0.25-0.5=mild
functional limitation; 0.5-1=moderate functional limitation; more than 1=significant functional limitation.
The proportion of participants achieving a clinically important reduction of >= 0.22 point in HAQ (disease-specific questionnaire) at Week 24 was evaluated.
HAQ was assessed using the set of observed cases (OC) at each assessment time.
An improvement of 0.22 units in HAQ-DI was considered to be a clinically significant improvement.
|
Week 24
|
|
Mean Change From Baseline in the Short-Form (SF-36) Health Survey Physical Component Score and Mental Component Score at Week 24
Aikaikkuna: Baseline and Week 24
|
SF- 36 investigates the standard of quality of life through a general health assessment and not specific to a particular disease, age or treatment group.
It is a 36-item questionnaire measuring 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health).
Each domain score ranges from 0 (worst) to 100 (best), with higher scores reflecting better health-related functional status.
Two summary scale scores were computed based on weighted combinations of the 8 domain scores: the Physical Component Summary and the Mental Component Summary.
SF-36 was assessed using the set of observed cases (OC) at each assessment time.
|
Baseline and Week 24
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Number of Participants With Infusion Reactions, Infectious Events and / or Other Adverse Events in the 24 Weeks After the Start of Treatment.
Aikaikkuna: Up to 24 Weeks
|
An infusion reaction is defined as an adverse event that occurs during infusion or within 24 hours after infusion of Rituximab.
All infectious events, whether considered related or not to Rituximab, were collected for the safety analysis of the study.
An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
|
Up to 24 Weeks
|
|
Mean Change From Baseline in Erythrocyte Sedimentation Rate (ESR)
Aikaikkuna: Baseline, Week 12, Week 24
|
Erythrocyte Sedimentation Rate is an acute phase reactant and a measure of inflammation.
|
Baseline, Week 12, Week 24
|
|
Mean Change From Baseline in C-reactive Protein (CRP).
Aikaikkuna: Baseline, Week 12, Week 24
|
CRP is an inflammation marker.
High levels of this protein indicate inflammation in diseases such as Rheumatoid Arthritis.
|
Baseline, Week 12, Week 24
|
|
Mean Change From Baseline in Swollen Joint Count (SJC)
Aikaikkuna: Baseline, Week 12, Week 24
|
A swollen joint count is the most specific clinical method to quantify abnormalities in participants with rheumatoid arthritis (RA).
It reflects the amount of inflamed synovial tissue.
|
Baseline, Week 12, Week 24
|
|
Mean Change From Baseline in Tender Joint Count (TJC)
Aikaikkuna: Baseline, Week 12, Week 24
|
A tender joint count is the most specific clinical method to quantify abnormalities in participants with rheumatoid arthritis (RA).
It is associated more with the level of pain.
|
Baseline, Week 12, Week 24
|
|
Mean Change From Baseline in Disease Activity Score 28 Joints (DAS28) Score
Aikaikkuna: Baseline, Week 12, Week 24
|
DAS28 is calculated from the number of swollen joints and tender joints using the 28-joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hr]) and Patient's Global Assessment of Disease Activity (participant-rated arthritis activity assessment) with transformed scores ranging 0 (minimum score) to 10 (maximum score); higher scores indicated greater affectation due to disease activity.
A DAS28 score of less than or equal to (=<) 3.2 = low disease activity, a DAS28 score of >3.2 to 5.1 = moderate to high disease activity.
|
Baseline, Week 12, Week 24
|
|
Mean Change From Baseline in Patient Global Assessment (100 mm VAS)
Aikaikkuna: Baseline, Week 12, Week 24
|
The Physician's Global Assessment of disease activity was assessed using a 0 to 100 mm horizontal visual analogue scale (VAS).
The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity).Change from Baseline = scores at observation minus score at Baseline.
An increase in score from Baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.
|
Baseline, Week 12, Week 24
|
|
Change in HAQ Score From Screening to Weeks 12 and 24
Aikaikkuna: Baseline, Week 12, Week 24
|
The Health Assessment Questionnaire-Disability Index (HAQ-DI) is a 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping and activities of daily living).
Responses in each functional area are scored from 0 to 3 (0=no difficulty and 3=inability to perform a task in that area).
HAQ-DI total scores expressed as overall mean score with range 0-3: 0-0.25=normal functioning; 0.25-0.5=mild
functional limitation; 0.5-1=moderate functional limitation; more than 1=significant functional limitation.
The number of participants achieving a clinically important reduction of >= 0.22 point in HAQ (disease-specific questionnaire) at Week 24 was evaluated.
HAQ was assessed using the set of observed cases (OC) at each assessment time.
An improvement of 0.22 units in HAQ-DI was considered to be a clinically significant improvement.
|
Baseline, Week 12, Week 24
|
|
Change in Pain Scale (100-mm VAS) From Screening to Weeks 12 and 24
Aikaikkuna: Baseline, Week 12, Week 24
|
Visual Analogue Scale (VAS) is a 100 millimeter (mm) scale.
Intensity of pain range: 0 mm=no pain to 100 mm=worst possible pain.
Change from Screening=scores at observation minus score at Screening.
An increase in score from Screening represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.
The change in pain scale was analyzed for the set of observed cases (OC) at each assessment time.
|
Baseline, Week 12, Week 24
|
|
Change in SF-36 Physical and Mental Component Scores From Screening to Week 12
Aikaikkuna: Baseline, Week 12
|
SF- 36 investigates the standard of quality of life through a general health assessment and not specific to a particular disease, age or treatment group.
It is a 36-item questionnaire measuring 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health).
Each domain score ranges from 0 (worst) to 100 (best), with higher scores reflecting better health-related functional status.
Two summary scale scores were computed based on weighted combinations of the 8 domain scores: the Physical Component Summary and the Mental Component Summary.
SF-36 was assessed using the set of observed cases (OC) at each assessment time.
|
Baseline, Week 12
|
|
Change in SF-36 Domain Scores From Screening to Week (Wk) 12 and 24
Aikaikkuna: Baseline, Week 12, Week 24
|
SF- 36 investigates the standard of quality of life through a general health assessment and not specific to a particular disease, age or treatment group.
It is a 36-item questionnaire measuring 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health).
Each domain score ranges from 0 (worst) to 100 (best), with higher scores reflecting better health-related functional status.
Two summary scale scores were computed based on weighted combinations of the 8 domain scores: the Physical Component Summary and the Mental Component Summary.
SF-36 was assessed using the set of observed cases (OC) at each assessment time.
|
Baseline, Week 12, Week 24
|
|
Percentage of Participants Achieving a Clinically Important Reduction of >= 0.22 Point in HAQ Score at Week 12.
Aikaikkuna: Week 12
|
The Health Assessment Questionnaire-Disability Index (HAQ-DI) is a 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping and activities of daily living).
Responses in each functional area are scored from 0 to 3 (0=no difficulty and 3=inability to perform a task in that area).
HAQ-DI total scores expressed as overall mean score with range 0-3: 0-0.25=normal functioning; 0.25-0.5=mild
functional limitation; 0.5-1=moderate functional limitation; more than 1=significant functional limitation.
The proportion of participants achieving a clinically important reduction of >= 0.22 point in HAQ (disease-specific questionnaire) at Week 24 was evaluated.
HAQ was assessed using the set of observed cases (OC) at each assessment time.
An improvement of 0.22 units in HAQ-DI was considered to be a clinically significant improvement.
|
Week 12
|
|
Percentage of Participants Achieving a Clinically Important Increase of >=5 Points in the SF-36 Physical and Mental Component Scores at Weeks 12 and 24.
Aikaikkuna: Week 12 and 24
|
SF- 36 investigates the standard of quality of life through a general health assessment and not specific to a particular disease, age or treatment group.
It is a 36-item questionnaire measuring 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health).
Each domain score ranges from 0 (worst) to 100 (best), with higher scores reflecting better health-related functional status.
Two summary scale scores were computed based on weighted combinations of the 8 domain scores: the Physical Component Summary and the Mental Component Summary.
SF-36 was assessed using the set of observed cases (OC) at each assessment time.
|
Week 12 and 24
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Sponsori
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Keskiviikko 1. heinäkuuta 2009
Ensisijainen valmistuminen (Todellinen)
Perjantai 1. kesäkuuta 2012
Opintojen valmistuminen (Todellinen)
Perjantai 1. kesäkuuta 2012
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Torstai 23. heinäkuuta 2015
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Torstai 23. heinäkuuta 2015
Ensimmäinen Lähetetty (Arvio)
Perjantai 24. heinäkuuta 2015
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Arvio)
Tiistai 2. helmikuuta 2016
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Sunnuntai 3. tammikuuta 2016
Viimeksi vahvistettu
Perjantai 1. tammikuuta 2016
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- ML22064
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Nivelreuma
-
RemeGen Co., Ltd.ValmisKeskivaikea ja vaikea RheumatoId-niveltulehdusKiina